Scinai Immunotherapeutics
SCNI
6 hedge funds and large institutions have $367K invested in Scinai Immunotherapeutics in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
260% more capital invested
Capital invested by funds: $102K → $367K (+$265K)
100% more funds holding
Funds holding: 3 → 6 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$158K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$73.1K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.64K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$515 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $177K | +$158K | +306 | New |
|
|
VIA
2
Vantage Investment Advisors
State College,
Pennsylvania
| $99K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $83K | +$73.1K | +142 | New |
|
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $5K | +$4.64K | +9 | New |
|
|
EWM
5
Edge Wealth Management
New York
| $2K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $1K | +$515 | +1 | New |
|
|
7
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$44K | -120 | Closed |
|
SCNI Hedge Fund Activity: Q1 2017 in Review
6 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2017, worth a combined $367K — up 260% from $102K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SCNI positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $158K. The largest seller was Bank of Montreal, exiting entirely with an estimated $44K sold.
- 6 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2017, up from 3 in Q4 2016.
- Funds reported $367K of Scinai Immunotherapeutics stock for Q1 2017, up 260% quarter-over-quarter.
- 4 funds opened new Scinai Immunotherapeutics positions in Q1 2017 and 1 closed out, a net change of +3 holders.
- The largest Scinai Immunotherapeutics buyer in Q1 2017 was Citadel Advisors, an estimated $158K added.
- The largest Scinai Immunotherapeutics seller in Q1 2017 was Bank of Montreal, an estimated $44K sold.
Based on aggregated 13F filings for Q1 2017.